Quince Therapeutics (QNCX) Total Liabilities (2018 - 2026)

Quince Therapeutics has reported Total Liabilities for 9 years, with the latest figure at $15.5 million in Q2 2026.

• On a quarterly basis, Total Liabilities fell 85.3% year-over-year to $15.5 million in Q2 2026; TTM through Jun 2026 was $15.5 million, a 85.3% decrease from a year earlier, with the FY2025 full-year figure at $129.2 million, up 53.25% from the prior year.
• Total Liabilities was $15.5 million for Q2 2026 at Quince Therapeutics, up from $11.0 million in the prior quarter.
• The five-year high for Total Liabilities was $129.2 million in Q4 2025, with the low at $2.0 million in Q2 2023.
• Average Total Liabilities over 5 years is $50.7 million, with a median of $48.5 million recorded in 2024.
• The sharpest annual moves came in 2024 and 2026: Total Liabilities surged 4401.08% in 2024, then slumped 87.63% in 2026.
• Over 5 years, Total Liabilities stood at $3.3 million in 2022, then soared by 2396.71% to $82.8 million in 2023, then climbed by 1.83% to $84.3 million in 2024, then soared by 53.25% to $129.2 million in 2025, then slumped by 88.0% to $15.5 million in 2026.
• The last three Total Liabilities figures came in at $15.5 million (Q2 2026), $11.0 million (Q1 2026), and $129.2 million (Q4 2025), per Business Quant data.